Search Results for “dialysis” – Page 4 – media

Health Asia

Organiser：Ecommerce Gateway Pakistan (Pvt.) Ltd Time：October 17-19, 2024 Address：Karachi Expo Center, University Rd, Gulshan-e-Iqbal, Karachi, Pakistan Exhibition hall：Karachi Expo Center Product range: Medical Supplies: Medical diagnostic equipment, pharmaceuticals, electronic medical equipment and instruments, rescue equipment, medical reagent equipment, disposable medical equipment. Hospital Supplies: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical medical instruments, medical clothing and bedding, hospital furniture, emergency equipment, maternal and child care equipment, sterilization equipment, orthopedic prostheses, air filtration devices, blood pressure diagnostic instruments, heart rate monitors, ultrasound equipment, X-ray diagnostic equipment, urology and transplantation services, dialysis machines, physical therapy equipment. Laboratory Equipment: Laboratory instruments and equipment, optical instruments and equipment, image analysis and processing systems, testing instruments and devices, quality inspection equipment, laboratory renovation and upgrading technology, consumables, and related software. Pharmaceutical and Healthcare: Ophthalmology drugs, orthopedic drugs, traditional Chinese medicine, western medicine, traditional Chinese medicine health care drugs, nutritious foods, pharmaceutical intermediates, ...
- Source: drugdu
- 158
- June 28, 2024
Fresenius Medical Care plans layoffs ahead of California plant closure

Dive Brief Fresenius Medical Care will lay off more than 300 people as part of a planned closure of a manufacturing plant in Concord, California. The cuts will begin in August and continue through mid-2025, according to a Worker Adjustment and Retraining Notification (WARN) filing with California. CEO Helen Giza told investors on a May 7 call that the company is moving production from California to Mexico to reduce costs and improve margins. Dive Insight Fresenius Medical Care, which makes dialysis equipment and operates dialysis centers around the world, is looking to tighten spending in its first year as an independent company. The firm was separated from parent company Fresenius in November, with Fresenius keeping a 32% stake. Giza told investors that “several initiatives are underway” to optimize Fresenius Medical Care’s manufacturing footprint and supply chain. The company will move all dialysis manufacturing operations from Concord, California, to a facility ...
- Source: drugdu
- 110
- June 1, 2024
RUSSIAN HEALTH CARE WEEK 2024

Organiser:ZAO Time:2- 6 Dec. 2024 address：Krasnopresnenskaya naberezhnaya, 14, Moscow, Russia Exhibition hall: Expocentre Exhibition Center Product range: Diagnostic equipment: X-ray diagnostic equipment, ultrasonic diagnostic equipment, functional examination equipment, endoscopy equipment, nuclear medicine equipment, experimental diagnostic equipment, pathological diagnostic equipment, diagnostic imaging equipment, chromatographic analyzer, consulting room analyzer, dialysis and transplant surgery Treatment equipment: clinical radiology equipment; Clinical testing equipment and reagents, ward nursing equipment, surgery equipment, radiotherapy equipment, nuclear medicine treatment equipment, physical and chemical equipment, laser equipment, dialysis treatment equipment, temperature freezing equipment, first aid equipment Auxiliary equipment: disinfection and sterilization equipment, refrigeration equipment, central suction and oxygen supply system, air conditioning equipment, pharmaceutical machinery and equipment, blood bank equipment, medical data processing equipment, medical video and photography equipment, medical air pump system cosmetic equipment; Ophthalmic equipment and treatment technology and materials, dental equipment and instruments, dental repair systems and instruments, oral plastic surgery materials and tools, dental lasers, ...
- Source: drugdu
- 154
- May 20, 2024
Medical Fair China 2024

Organiser:Messe Düsseldorf Time:21- 23 August 2024 address：No. 688 East Suzhou Avenue, Suzhou Industrial Park, Suzhou City Exhibition hall: Suzhou International Expo Centre, China Product range: Hospital facilities and equipment: Medical electronic instruments, ultrasound instruments, X-ray equipment, medical optical instruments, clinical examination and analysis instruments, dental equipment and materials, hemodialysis equipment, anesthesia and respiratory equipment, disposable medical supplies, dressings and hygiene materials, all kinds of surgical instruments Hospital wards, operating rooms, emergency room equipment, hospital office equipment, laboratory equipment, beds, operating tables, operating table spotlights, inspection Check the bed, gums and all kinds of hospital furniture Medical care equipment: all kinds of medical and home rehabilitation physiotherapy products About CDMEE： Jiangsu Suzhou Medical Device Innovation Exhibition (Medical Fair China) with the theme of “smart health”, directly and comprehensively serving the medical device industry from the source to the terminal of the entire medical industry chain. Gather advanced medical technology products at ...
- Source: drugdu
- 152
- May 17, 2024
Hengrui Pharmaceuticals Innovative Drug SHR-2173 Injection for IgA Nephropathy Indication Approved for Clinical Use

Recently, Hengrui Pharmaceuticals’ subsidiary Guangdong Hengrui Pharmaceuticals Co., Ltd. received the Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, approving SHR-2173 Injection, a Class 1 new drug, to carry out clinical trials for IgA nephropathy. At present, there is no similar drug to SHR-2173 on the market or in the clinical development stage at home and abroad. IgA nephropathy is a group of autoimmune glomerulonephritis characterized by IgA deposition in the glomerular mesangial area. Typical clinical manifestations can be seen in microscopic hematuria, and patients have a history of mucosal (e.g., upper respiratory tract, gastrointestinal tract) infections, which is the most common primary glomerulopathies worldwide, and also a major cause of chronic kidney disease (CKD) and renal failure. In China, IgA nephropathy accounts for 45% of primary glomerular diseases in China. There are geographical differences in the incidence of the disease, and the peak ...
- Source: drugdu
- 75
- May 16, 2024
FDA Approves Azurity Pharmaceuticals’ Myhibbin as an Oral Suspension for Organ Transplant Recipients

Don Tracy, Associate Editor Myhibbin is reportedly the first FDA-approved liquid formulation of mycophenolate, a key immunosuppressant used to prevent organ rejection in transplant recipients. Axurity Pharmaceuticals announced that the FDA has officially approved Myhibbin as a ready-to-use mycophenolate mofetil oral suspension for organ transplant patients. Myhibbin is the first FDA-approved liquid formulation of mycophenolate, which is used to avoid organ rejection in transplant recipients, according to Azurity. The company stated that this approval provides a significant new option for both pediatric patients above the age of three months and adults who have undergone kidney, heart, or liver transplants.1 “We are very pleased that adult and pediatric organ transplant recipients will soon have access to the only FDA-approved ready-to-use oral liquid formulation of mycophenolate,” said Richard Blackburn, CEO, Azurity Pharmaceuticals, in a press release. “Patients are our priority, and our purpose is to bring them new formulations that help them ...
- Source: drugdu
- 77
- May 8, 2024
New Drug Application of Zydus’ Desidustat tablets by China Medical System Holdings accepted in China

Zydus Lifesciences announced that the New Drug Application (NDA) of Desidustat Tablets has been accepted by the National Medical Products Administration of China (NMPA). CMS International Development and Management, a wholly-owned subsidiary of China Medical System Holdings (CMS) obtained an exclusive license for the Product from Zydus in 2020. Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of functioning of kidneys and eventually leads to kidney failure. Healthy kidneys naturally secrete a hormone called Erythropoietin (EPO), which stimulates red blood cell production also known as erythropoiesis. When kidneys are impaired as in patients suffering from Chronic Kidney Disease, EPO production is impaired, leading to development of anaemia. HIF-PHI promotes erythropoiesis through increasing endogenous erythropoietin, reducing hepcidin thereby improves iron availability. Discovered and developed by Zydus, Desidustat is being marketed by the group ...
- Source: https://www.biospace.com/article/releases/china-medical-system-new-drug-application-of-desidustat-tablets-accepted-in-china/
- 134
- May 3, 2024
Nestlé India and Dr Reddy’s announces joint venture

The partnership will bring together the global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) with the commercial strengths of Dr. Reddy’s in India Nestlé India and Dr. Reddy’s Laboratories both together referred as “JV Partners”, today announced that they have entered into a definitive agreement to form a joint venture (“JV Company”) to bring innovative nutraceutical brands to consumers in India and other agreed territories. The partnership will bring together the global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) with the commercial strengths of Dr. Reddy’s in India. The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios in categories such as metabolic, hospital nutrition, general wellness , women’s health and child nutrition for consumers across India. The JV Company will be ...
- Source: drugdu
- 116
- April 29, 2024
Researchers suggest treatments for rare diseases could reduce burden of kidney disease

Rare kidney diseases are a group of conditions which account for over 5% of people living with chronic kidney disease A new study led by University College London (UCL) and the UK Kidney Association has suggested that treatments for rare diseases could significantly reduce the burden of kidney disease for patients and the NHS. Published in The Lancet in alignment with World Kidney Day (14 March 2024), the study draws on the largest kidney disease dataset ever created, the UK’s National Registry of Rare Kidney Disease (RaDaR). Affecting over seven million adults, according to Kidney Research UK, chronic kidney disease (CKD) is characterised by the gradual loss of kidney function over a period of months to years. Rare kidney diseases such as cystinosis and Fabry disease are a group of conditions that affect less than one in 2,000 people, accounting for over 5% of people with CKD. Researchers charted the ...
- Source: drugdu
- 78
- March 22, 2024
Inclusion of noncommunicable disease care in response to humanitarian emergencies will help save more lives

Noncommunicable diseases (NCDs), such as cardiovascular disease, cancer, chronic respiratory disease and diabetes, are responsible for 75% of deaths worldwide. People affected by humanitarian emergencies are at increased risk of NCDs. It is estimated that strokes and heart attacks are up to 3 times more likely following a disaster. However, care and treatment for NCDs are often not included as a standard part of humanitarian emergency preparedness and response, which focus on the most immediate needs. To support integration of essential services for NCDs into emergency preparedness and humanitarian response, the World Health Organization (WHO), the Kingdom of Denmark, the Hashemite Kingdom of Jordan, the Republic of Kenya, and UNHCR, the UN Refugee Agency, are jointly convening a global high-level technical meeting on NCDs in humanitarian settings on 27-29 February in Copenhagen, Denmark. Humanitarian emergencies in recent years are becoming more complex and interconnected. Hunger and shortages of essential goods ...
- Source: drugdu
- 121
- February 29, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.